Nasdaq
$34.49▼ 0.06%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.68BShares out 48.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
13- 10.9Regular26.10.10 01:574Ownership#●●●
UroGen Pharma Ltd.
Insider Chris Degnan of UroGen Pharma Ltd. filed a Form 4 statement of changes in beneficial ownership of securities on October 8, 2026. This filing serves as the official SEC notification regarding the insider's change in shareholdings.…more
$34.49-0.06%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.9Pre-market26.10.09 19:23144Ownership
UroGen Pharma Ltd.
Insider Chris Degnan of UroGen Pharma Ltd. has filed SEC Form 144 to report a proposed sale of company securities. This is a standard filing disclosing an insider's plan to dispose of shares.…more
$34.49-0.06%vs prev closeView filingShare - 9.9Regular26.09.10 03:374Ownership
UroGen Pharma Ltd.
Insider Mark Schoenberg of UroGen Pharma Ltd. reported a change in beneficial ownership of securities as of September 7, 2026. This Form 4 filing details the insider's transaction activity with the SEC.…more
$34.49-0.06%vs prev closeView filingShare
12 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 6d agoPre-market26.10.19 21:00#●●●#●●●
UroGen Pharma Announces FDA Acceptance of NDA for Bladder Cancer Drug UGN-103…more
UroGen Pharma announced that the FDA has accepted its New Drug Application for UGN-103, a treatment for recurrent bladder cancer. The FDA has set a target action date of June 14, 2027, for the regulatory review process.…more
$34.49-0.06%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.4Pre-market26.09.04 21:00
●●●●●●●● ●●●●● ●●●●●●
UroGen Pharma announced the grant of 117,100 restricted stock units to 19 new employees as an employment inducement. This is a standard compensation practice for talent acquisition and does not significantly impact existing shareholders.…more
$34.49-0.06%vs prev close - 8.20Pre-market26.08.20 20:02
●●●●●●●● ●●●●● ●●●●●●
UroGen Pharma has secured a research license and exclusive options to develop oncology products using IntraGel's proprietary drug delivery platform. The agreement also includes an equity investment in IntraGel to support the development of their investigational cancer therapies.…more
$34.49-0.06%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report